
Repairing precise neural microcircuitry after cortical injury remains a pivotal challenge. Human brain organoids (hBOs) are a promising cell source, but disorganized integration limits their therapeutic potential. Here, we demonstrated that targeted neuromodulation, steered by endogenous narrowband gamma (NBG) rhythms, instructed structural and functional integration of hBO grafts in the injured adult mouse visual cortex. Using a neural interface system, we promoted general graft-host coupling and then delivered NBG-rhythmic stimulation to specific functional clusters. This strategy guided the emergence of layer 4-appropriate molecular and functional properties in grafts, enabled bidirectional connectivity with the host visual circuit, and supported the development of advanced visual processing, including direction selectivity in hBO neurons. Electrophysiologically, graft spiking phase locked to host NBG oscillations. Behaviorally, host visual acuity and contrast sensitivity were significantly restored. Our work established a framework for circuit-level repair, highlighting a synergistic strategy that moves beyond cell replacement to direct the assembly of neural grafts.
In a study recently published in Nature, Belk et al.1 use somatic mutations to demonstrate that bone marrow-derived cells enter the aging human brain and resemble microglia. The aged microglial compartment may therefore have a substantial hematopoietic contribution, and its clonal composition may prove important for stem-cell-based microglial replacement.
Cardiac patches implanted onto the heart surface are a prospective treatment for myocardial infarction. In this issue of Cell Stem Cell, Xie et al. provide evidence that patches matching myocardial electroconductivity not only reestablish cardiac conduction after injury but also induce endothelial differentiation of epicardial cells to promote heart repair.
China’s 2026 reform creates a new dynamic regulatory architecture for stem cell and other advanced biomedical technology research and translation that moves these areas beyond the drug-versus-technology divide. Through revocable clinical-use authorization, life cycle surveillance, and mandatory exit, it seeks to align clinical access with safety oversight and evidentiary validation.
Recreating bone remodeling remains challenging in bone organoids. In this issue of Cell Stem Cell, Pinho et al.1 develop bone organoids within liquefied microcapsules that support osteoblast, osteocyte, and osteoclast differentiation without exogenous differentiation inducers. This model supports matrix deposition and resorption, enabling investigation of cellular interactions underlying bone remodeling.